ADMA Biologics Inc(ADMA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ADMA ADMA Biologics Inc

已收盘 07-31 16:00:00 EDT

8.46

-0.21

-2.42%

盘后8.46

+0.000.00%

19:44 EDT

最高8.66	最低8.35	成交量161.99万
今开8.58	昨收8.67	日振幅3.58%
总市值19.65亿	流通市值18.47亿	总股本2.32亿
成交额1,368万	换手率0.74%	流通股本2.18亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ADMA","market":"US","secType":"STK","nameCN":"ADMA Biologics Inc","latestPrice":8.46,"timestamp":1785528000000,"preClose":8.67,"halted":0,"volume":1619915,"hourTrading":{"tag":"盘后","latestPrice":8.46,"preClose":8.46,"latestTime":"19:44 EDT","volume":66301,"amount":561030.8692,"timestamp":1785541455630,"change":0,"changeRate":0,"amplitude":0.006229},"delay":0,"changeRate":-0.024221453287197124,"floatShares":218378323,"shares":232324283,"eps":0.68,"marketStatus":"已收盘","change":-0.21,"latestTime":"07-31 16:00:00 EDT","open":8.58,"high":8.66,"low":8.35,"amount":13677487.446397498,"amplitude":0.035755,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.68,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1785744000000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":8.67,"preHourTrading":{"tag":"盘前","latestPrice":8.57,"preClose":8.67,"latestTime":"09:29 EDT","volume":11154,"amount":96045.84475199999,"timestamp":1785504599999,"change":-0.1,"changeRate":-0.011534,"amplitude":0.147636},"postHourTrading":{"tag":"盘后","latestPrice":8.46,"preClose":8.46,"latestTime":"19:44 EDT","volume":66301,"amount":561030.8692,"timestamp":1785541455630,"change":0,"changeRate":0,"amplitude":0.006229},"volumeRatio":0.779491,"impliedVol":0.6666,"impliedVolPercentile":0.6096},"requestUrl":"/m/hq/s/ADMA","defaultTab":"news","newsList":[{"id":"2642132239","title":"ADMA Biologics遭证券欺诈集体诉讼，投资者损失惨重","url":"https://stock-news.laohu8.com/highlight/detail?id=2642132239","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642132239?lang=zh_cn&edition=full","pubTime":"2026-06-12 03:03","pubTimestamp":1781204580,"startTime":"0","endTime":"0","summary":"霍华德·G·史密斯律师事务所近日提醒ADMA Biologics公司股东，该公司正面临一桩证券欺诈集体诉讼，并鼓励在指定期间内购买其股票并遭受损失的投资者积极咨询相关法律权益。　　根据多家律师事务所发布的消息，该集体诉讼已于美国新泽西州联邦地区法院正式提起。诉讼代表所有在2024年8月9日至2026年3月25日期间购买或以其他方式收购ADMA Biologics证券的投资者。投资者申请成为首席原告的截止日期为2026年8月10日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-12/doc-inicaraa2021196.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["161027","ADMA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130836176","title":"异动解读 | 撤回长期业绩指引及市场竞争加剧，ADMA Biologics盘前大跌21.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=1130836176","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130836176?lang=zh_cn&edition=full","pubTime":"2026-05-07 16:15","pubTimestamp":1778141757,"startTime":"0","endTime":"0","summary":"ADMA Biologics Inc（ADMA）今日盘前股价大跌21.63%，引发了市场的广泛关注。消息面上，公司决定撤回其长期业绩指引，主要原因是血浆制品与免疫球蛋白市场日益激烈的竞争态势。这一调整反映出当前行业竞争格局对该公司未来增长预期产生了实质性影响，导致投资者信心受挫。撤回业绩指引通常被视为负面信号，表明管理层对市场环境变化持审慎态度，并预示着行业可能进入新一轮调整周期。市场动态的快速演变迫使企业重新评估原有战略规划，以更灵活的姿态应对不确定性，但短期内这一举措加剧了股价的波动。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ADMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164083054","title":"异动解读 | 撤回长期业绩指引及市场竞争加剧，ADMA Biologics夜盘大跌24.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=1164083054","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164083054?lang=zh_cn&edition=full","pubTime":"2026-05-07 08:04","pubTimestamp":1778112298,"startTime":"0","endTime":"0","summary":"ADMA Biologics Inc（ADMA）今日夜盘股价大跌24.01%，引发了市场的广泛关注。消息面上，公司决定撤回其长期业绩指引，主要原因是血浆制品与免疫球蛋白市场日益激烈的竞争态势。这一调整反映出当前行业竞争格局对该公司未来增长预期产生了实质性影响，导致投资者信心受挫。撤回业绩指引通常被视为负面信号，表明管理层对市场环境变化持审慎态度，并预示着行业可能进入新一轮调整周期。市场动态的快速演变迫使企业重新评估原有战略规划，以更灵活的姿态应对不确定性，但短期内这一举措加剧了股价的波动。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ADMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123257218","title":"异动解读 | ADMA Biologics盘后大跌26.88%，因撤回长期业绩指引及市场竞争加剧","url":"https://stock-news.laohu8.com/highlight/detail?id=1123257218","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123257218?lang=zh_cn&edition=full","pubTime":"2026-05-07 04:51","pubTimestamp":1778100702,"startTime":"0","endTime":"0","summary":"ADMA Biologics Inc（ADMA）今日盘后股价大幅下跌26.88%，这一剧烈波动引起了市场的广泛关注。消息面上，公司决定撤回其长期业绩指引，主要原因是血浆制品与免疫球蛋白市场日益激烈的竞争态势。这一调整反映出当前行业竞争格局对该公司未来增长预期产生了实质性影响，导致投资者信心受挫。撤回业绩指引通常被视为负面信号，表明管理层对市场环境变化持审慎态度，并预示着行业可能进入新一轮调整周期。市场动态的快速演变迫使企业重新评估原有战略规划，以更灵活的姿态应对不确定性，但短期内这一举措加剧了股价的波动。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ADMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122459342","title":"ADMA Biologics Inc撤回长期业绩指引 主因血浆制品与免疫球蛋白市场竞争加剧","url":"https://stock-news.laohu8.com/highlight/detail?id=1122459342","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122459342?lang=zh_cn&edition=full","pubTime":"2026-05-07 04:24","pubTimestamp":1778099068,"startTime":"0","endTime":"0","summary":"鉴于血浆制品(PDT)与免疫球蛋白(Ig)市场日益激烈的竞争态势，ADMA Biologics Inc决定撤回其长期业绩指引。这一调整反映出当前行业竞争格局对该公司未来增长预期产生的实质性影响。市场动态的快速演变迫使企业重新评估原有战略规划，以更灵活的姿态应对不确定性。此次指引撤回也向投资者传递出管理层对市场环境变化的审慎态度，预示着行业可能进入新一轮调整周期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADMA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172188939","title":"AD Ports Group宣布ADMA与Orbitworks签署协议，获取先进地球观测服务","url":"https://stock-news.laohu8.com/highlight/detail?id=1172188939","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172188939?lang=zh_cn&edition=full","pubTime":"2026-05-04 19:02","pubTimestamp":1777892569,"startTime":"0","endTime":"0","summary":"阿布扎比港口集团（AD Ports Group）近日宣布，其旗下子公司ADMA Biologics已与Orbitworks公司达成合作协议，旨在获取先进的地球观测服务。\n根据协议内容，通过卫星采集的智能数据将显著提升港口运营管理与监控能力。这项合作将利用前沿的遥感技术优化港口作业效率。\n此次合作标志着AD Ports Group在数字化港口管理领域迈出重要一步。卫星衍生情报的运用将为港口日常运营提供实时决策支持。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195089238","title":"ADMA生物制药获FDA批准扩大Asceniv™适应症范围 覆盖两岁及以上儿科免疫缺陷患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1195089238","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195089238?lang=zh_cn&edition=full","pubTime":"2026-05-04 19:01","pubTimestamp":1777892478,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式批准ADMA生物制药扩大其免疫球蛋白产品Asceniv™的标签适用范围。此次标签扩展将允许该药物用于治疗两岁及以上的儿科免疫缺陷患者，为这一脆弱群体提供新的治疗选择。\nAsceniv™作为一款针对原发性免疫缺陷症（PIDD）的静脉注射免疫球蛋白（IVIG）疗法，此次适应症扩展现标志着其在儿科医疗领域取得重要进展。该批准基于临床试验数据，证实了药物在低龄免疫缺陷患者中的安全性与有效性。\n此次监管突破有望为ADMA生物制药开拓新的患者群体，进一步巩固其在免疫球蛋白细分市场的竞争地位。公司表示将尽快推进该适应症的商业化进程，以满足儿科患者的临床需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151526092","title":"ADMA Biologics 驳斥关键指控，以澄清市场对其商业惯例与运营的误解","url":"https://stock-news.laohu8.com/highlight/detail?id=1151526092","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151526092?lang=zh_cn&edition=full","pubTime":"2026-03-27 19:06","pubTimestamp":1774609617,"startTime":"0","endTime":"0","summary":"ADMA Biologics Inc (ADMA Biologics) 针对近期市场流传的若干关键指控予以坚决驳斥。此举旨在消除外界对其商业运营模式和日常操作所产生的困惑与误解。公司明确表示，其业务实践严格遵守相关法规，运营活动透明且规范。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADMA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175737022","title":"ADMA Biologics：作为标准免疫球蛋白治疗失败患者的后线疗法，Asceniv 定位独特并享有溢价定价","url":"https://stock-news.laohu8.com/highlight/detail?id=1175737022","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175737022?lang=zh_cn&edition=full","pubTime":"2026-03-27 19:04","pubTimestamp":1774609444,"startTime":"0","endTime":"0","summary":"对于标准免疫球蛋白治疗反应不佳的患者群体，ADMA Biologics Inc 旗下的 Asceniv 凭借其独特的治疗定位，已成为重要的后线治疗方案。该产品的差异化优势使其在市场中独树一帜，进而支撑了其较高的定价水平。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149236728","title":"ADMA Biologics Inc驳斥做空报告：指其曲解Asceniv在IVIG市场效用与竞争定位","url":"https://stock-news.laohu8.com/highlight/detail?id=1149236728","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149236728?lang=zh_cn&edition=full","pubTime":"2026-03-27 19:03","pubTimestamp":1774609394,"startTime":"0","endTime":"0","summary":"ADMA Biologics Inc近日回应一份做空报告，明确指出该报告对旗下产品Asceniv在静脉注射免疫球蛋白（IVIG）市场的实际效用及竞争地位存在严重曲解和混淆。公司强调，报告中的指控未能准确反映Asceniv的临床价值与市场定位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159924090","title":"ADMA Biologics 发布声明驳斥 Culper Research 毫无根据、误导且不实的指控","url":"https://stock-news.laohu8.com/highlight/detail?id=1159924090","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159924090?lang=zh_cn&edition=full","pubTime":"2026-03-27 19:01","pubTimestamp":1774609283,"startTime":"0","endTime":"0","summary":"ADMA Biologics Inc (ADMA Biologics) 已就 Culper Research 近期发布的报告发表正式声明。该公司明确指出，该报告中的指控均属毫无根据、具有误导性且内容失实。ADMA Biologics 坚决否认报告中的所有不实陈述，并致力于维护其运营的完整性及对股东和患者的承诺。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADMA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140548613","title":"ADMA Biologics：做空报告依据不明来源的推测性论断，可信度存疑","url":"https://stock-news.laohu8.com/highlight/detail?id=1140548613","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140548613?lang=zh_cn&edition=full","pubTime":"2026-03-25 18:32","pubTimestamp":1774434723,"startTime":"0","endTime":"0","summary":"一份针对ADMA Biologics Inc (ADMA Biologics) 的做空报告，其核心论点似乎建立在推测性论断之上，而这些论断的来源既不明朗，也缺乏可靠性支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100408182","title":"异动解读 | ADMA Biologics宣布加速股票回购协议，盘中大涨5.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=1100408182","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100408182?lang=zh_cn&edition=full","pubTime":"2026-03-02 22:43","pubTimestamp":1772462580,"startTime":"0","endTime":"0","summary":"ADMA Biologics Inc（ADMA）今日盘中大涨5.20%，引起了市场的广泛关注。消息面上，ADMA Biologics宣布与摩根大通达成一项规模达1.25亿美元的加速股票回购协议，该协议是其2026年总额2亿美元股票回购计划的重要组成部分。此举彰显了管理层对公司长期价值的信心，并体现了其优化资本结构、提升股东回报的坚定承诺。根据协议，ADMA将通过此次加速回购机制立即回购大部分预定股份，约占回购计划总额的62.5%。市场分析认为，股票回购计划通常被视为积极的资本配置行动，可能减少流通股数量，从而对股价产生支撑和提振作用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ADMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125548186","title":"ADMA Biologics宣布与摩根大通达成1.25亿美元快速股票回购协议，作为2026年总额2亿美元股票回购计划组成部分","url":"https://stock-news.laohu8.com/highlight/detail?id=1125548186","media":"美股速递","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125548186?lang=zh_cn&edition=full","pubTime":"2026-03-02 20:02","pubTimestamp":1772452979,"startTime":"0","endTime":"0","summary":"ADMA Biologics近日宣布与摩根大通达成一项规模达1.25亿美元的加速股票回购协议。这项交易是该公司2026年总额2亿美元股票回购计划的重要环节，标志着其资本配置战略进入新阶段。根据协议条款，ADMA将通过此次加速回购机制立即回购大部分预定股份。通过灵活运用现金储备实施股份回购，ADMA旨在平衡业务增长需求与股东利益最大化。剩余部分将根据市场条件和监管要求适时推进。这种分阶段执行策略既保持了财务灵活性，又为未来潜在投资机会预留了空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADMA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614886038","title":"Adma Biologics Inc盘中异动 急速下挫5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614886038","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614886038?lang=zh_cn&edition=full","pubTime":"2026-02-25 04:22","pubTimestamp":1771964533,"startTime":"0","endTime":"0","summary":"北京时间2026年02月25日04时22分，Adma Biologics Inc股票出现异动，股价快速下跌5.10%。截至发稿，该股报15.46美元/股，成交量155.45万股，换手率0.65%，振幅5.40%。Adma Biologics Inc股票所在的生物技术行业中，整体涨幅为0.01%。Adma Biologics Inc公司简介：ADMA Biologics Inc是一家端到端的商业生物制药公司，致力于生产、营销和开发特殊的血浆衍生生物制剂，用于治疗有感染风险的免疫缺陷患者和其他有某些传染病风险的患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602250422139541d933&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602250422139541d933&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ADMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518244776","title":"Adma Biologics Inc2024财年实现净利润1.98亿美元，同比增加801.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518244776","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518244776?lang=zh_cn&edition=full","pubTime":"2025-03-09 00:01","pubTimestamp":1741449682,"startTime":"0","endTime":"0","summary":"3月9日，Adma Biologics Inc公布财报，公告显示公司2024财年净利润为1.98亿美元，同比增加801.13%；其中营业收入为4.26亿美元，同比增加65.12%，每股基本收益为0.85美元。从资产负债表来看，Adma Biologics Inc总负债1.38亿美元，其中短期债务1.22百万美元，资产负债比为3.55，流动比率为0.06。机构评级：截至2025年3月9日，当前有3家机构对Adma Biologics Inc目标价做出预测，其中目标均价为27.33美元，其中最低目标价为25.00美元，最高目标价为32.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000250abef98ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000250abef98ab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ADMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517910218","title":"Adma Biologics Inc盘中异动 急速拉升5.11%报17.88美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517910218","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517910218?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:42","pubTimestamp":1741185758,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时42分，Adma Biologics Inc股票出现波动，股价快速上涨5.11%。截至发稿，该股报17.88美元/股，成交量38.2961万股，换手率0.16%，振幅5.35%。Adma Biologics Inc股票所在的生物技术行业中，整体涨幅为0.70%。Adma Biologics Inc公司简介：ADMA Biologics Inc是一家端到端的商业生物制药公司，致力于生产、营销和开发特殊的血浆衍生生物制剂，用于治疗有感染风险的免疫缺陷患者和其他有某些传染病风险的患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305224238a260cb48&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305224238a260cb48&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ADMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516670663","title":"坎托菲茨杰拉德公司：重申ADMA Biologics(ADMA.US)评级，由增持调整至增持评级, 目标价由25.00美元调整至25.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516670663","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516670663?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:54","pubTimestamp":1741100071,"startTime":"0","endTime":"0","summary":"坎托菲茨杰拉德公司：重申ADMA Biologics(ADMA.US)评级，由增持调整至增持评级, 目标价由25.00美元调整至25.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/04225448522189.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ADMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516672229","title":"Adma Biologics Inc盘中异动 快速下跌8.47%报14.49美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516672229","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516672229?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:32","pubTimestamp":1741098761,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时32分，Adma Biologics Inc股票出现异动，股价急速下挫8.47%。Adma Biologics Inc股票所在的生物技术行业中，整体涨幅为0.25%。Adma Biologics Inc公司简介：ADMA Biologics Inc是一家端到端的商业生物制药公司，致力于生产、营销和开发特殊的血浆衍生生物制剂，用于治疗有感染风险的免疫缺陷患者和其他有某些传染病风险的患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223241a25f04e8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223241a25f04e8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ADMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116609081","title":"ADMA Biologics 2024年第四季度调整后每股收益（EPS）为0.14美元，低于预期的0.15美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1116609081","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116609081?lang=zh_cn&edition=full","pubTime":"2025-03-04 05:18","pubTimestamp":1741036692,"startTime":"0","endTime":"0","summary":"ADMA Biologics 2024年第四季度调整后每股收益（EPS）为0.14美元，低于预期的0.15美元。以上内容来自Benzinga Earnings专栏，原文如下：ADMA Biologics Q4 2024 Adj. EPS $0.14 Misses $0.15 Estimate","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADMA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.admabiologics.com","stockEarnings":[{"period":"1week","weight":0.0358},{"period":"1month","weight":0.0358},{"period":"3month","weight":-0.1759},{"period":"6month","weight":-0.4988},{"period":"1year","weight":-0.5336},{"period":"ytd","weight":-0.5247}],"compareEarnings":[{"period":"1week","weight":0.0048},{"period":"1month","weight":-0.0068},{"period":"3month","weight":0.0292},{"period":"6month","weight":0.0719},{"period":"1year","weight":0.169},{"period":"ytd","weight":0.0876}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"ADMA Biologics, Inc.于2004年6月24日作为新泽西州公司成立，并于2007年7月16日在特拉华州重新注册。该公司是一家总部位于美国的端到端商业化生物制药公司，致力于为免疫缺陷患者和有特定传染病风险的人群制造、营销和开发专科生物制品。它销售三种经FDA批准的产品——ASCENIV、BIVIGAM和Nabi-HB，这些产品在其位于佛罗里达州的工厂生产，并运营着获得FDA许可的血浆采集中心。","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":0.021016},{"month":2,"riseRate":0.5,"avgChangeRate":-0.01871},{"month":3,"riseRate":0.583333,"avgChangeRate":0.064012},{"month":4,"riseRate":0.666667,"avgChangeRate":0.034208},{"month":5,"riseRate":0.583333,"avgChangeRate":0.031016},{"month":6,"riseRate":0.25,"avgChangeRate":-0.047592},{"month":7,"riseRate":0.75,"avgChangeRate":0.099425},{"month":8,"riseRate":0.272727,"avgChangeRate":0.003287},{"month":9,"riseRate":0.181818,"avgChangeRate":-0.032166},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.041559},{"month":11,"riseRate":0.636364,"avgChangeRate":0.093715},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.060542}],"exchange":"NASDAQ","name":"ADMA Biologics Inc","nameEN":"ADMA Biologics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ADMA Biologics Inc(ADMA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供ADMA Biologics Inc(ADMA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"ADMA Biologics Inc,ADMA,ADMA Biologics Inc股票,ADMA Biologics Inc股票老虎,ADMA Biologics Inc股票老虎国际,ADMA Biologics Inc行情,ADMA Biologics Inc股票行情,ADMA Biologics Inc股价,ADMA Biologics Inc股市,ADMA Biologics Inc股票价格,ADMA Biologics Inc股票交易,ADMA Biologics Inc股票购买,ADMA Biologics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ADMA Biologics Inc(ADMA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供ADMA Biologics Inc(ADMA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}